華潤三九(000999.SZ)擬1.9億元收購深圳華潤堂100%股權
格隆匯 12 月 15日丨華潤三九(000999.SZ)公佈,為落實公司業務發展戰略,拓展公司線上業務,打造國藥業務平台,公司擬與華潤堂有限公司(“華潤堂”)簽署《關於華潤堂(深圳)醫藥連鎖有限公司之股權轉讓合同》,擬收購華潤堂持有的華潤堂(深圳)醫藥連鎖有限公司(“深圳華潤堂”或“目標公司”)100%股權。此次交易價款共計人民幣約1.9億元,資金來源為公司自有資金。
深圳華潤堂主要從事內地市場的線下門店零售業務,產品涵蓋滋補品、保健品、藥品、中藥飲片、健康食品、個人護理等多個領域,其中以中藥滋補品為主。目前“華潤堂”商標在內地註冊的類別主要集中在5類、35類和44類,由華潤集團所有,深圳華潤堂已簽署有關商標使用許可合同,獲得“華潤堂”商標在內地的授權使用許可。
隨着國民收入水平提高,大眾健康觀念的提升,中藥滋補保健品市場呈現快速增長。根據前瞻產業研究院發佈的《中國中藥保健品行業市場需求與投資規劃分析報告》,2018年中國保健品行業規模達2875億,其中中藥保健品規模890.2億元,佔比達到31%,僅次於膳食營養補充劑。預計中藥保健品2024年行業市場規模將達到1493億元,市場前景廣闊。深圳華潤堂在中藥滋補和健康保健領域深耕多年,目前主要從事內地市場的零售業務,產品涵蓋滋補品、保健品、藥品、中藥飲片、健康食品、個人護理等多個領域,並以中藥滋補品為主。
此次收購符合華潤三九戰略方向,公司將基於深圳華潤堂擁有的中藥滋補保健品的基礎及線上線下經營資質及零售運營經驗,與華潤三九的中醫藥業務資源及品牌建設能力協同,積極轉型發展深圳華潤堂線上中藥滋補品牌業務。同時,與公司國藥業務逐步整合,藉助深圳華潤堂相關資質探索中醫藥服務,將深圳華潤堂打造成為國藥業務發展平台。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.